Statins and the Urinary Proteome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate whether statines (rosuva- and pravastatin) induce tubular proteinuria.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proximal tubular cells of the kidney are responsible for reabsorption of proteins from the tubular lumen. In a study using Opossum kidney (OK) cells, receptor-mediated protein endocytosis was reduced by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, which are widely used for therapeutic reduction of plasma cholesterol levels (1). In a subsequent in vitro study protein endocytosis in human mixed proximal/distal kidney tubular cells was investigated in the presence and absence of statins to explore the possible clinical relevance of the observations in OK cells (2). The uptake of FITC-labeled albumin in these cultures occurred selectively into proximal tubular cells while it was absent in distal tubular/collecting duct cells. Three statins (simvastatin, pravastatin, and rosuvastatin) significantly inhibited the uptake of protein in a concentration-dependent way. This inhibitory effect of statins could be prevented by the co-addition of mevalonate, the product of HMG-CoA reductase. This effect was not the result of a statin-induced cytotoxicity since cell-viability was unaffected.

These data suggest that statins have the potential to inhibit albumin uptake by the human proximal nephron as a result of inhibition of HMG-CoA reductase in the proximal tubule cells. A reduced prenylation of some proteins critically involved in endocytosis has been put forward as the underlying mechanism.

Knowing these data it has been suggested that the occurrence of proteinuria in some patients treated with high statin doses is the result of a reduced tubular reabsorption/endocytosis of normally filtered proteins. To further explore the clinical relevance of such a mechanism, the composition of the urinary proteome under statin treatment will be investigated in normal healthy volunteers by two-dimensional gel electrophoresis based proteomics analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Statin Induced Proteinuria

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

statins proteinuria proteomic analysis healthy volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosuvastatin-Crestor

Intervention Type DRUG

Pravastatin-Pravasine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male, age range: 25 - 65 years
* Non-smoker
* Proteinuria: \< 60 mg/24 hours
* Dipstick negative hematuria
* Bloodpressure: \< 135 mm systolic, \< 85 mm dyastolic
* Waist circumference: \< 94 cm

Exclusion Criteria

* Treatment with lipid-lowering drugs \<1 year prior to the study
* Known history of diabetes or fasting glucose level: \< 110 mg/dl
* Anti-hypertensive medication
* Life-expectancy \< 1 year
* Pharmacological treatment with inotropes
* Acute or chronic inflammatory process, use if anti-inflammatory drugs or immunosuppression
* Clinically active malignant disease
* Administration of any investigational drug within 30 days preceding study start and during the study
* Known intolerance to rosuvastatin or other statins
* Acute or chronic liver disease or ALAT\>2.0 x upper limit of normal (ULN) at enrolment visit.
* Chronic muscle disease such as dermatomyositis or polymyositis or unexplained creatinine kinase (CK) above 3 x ULN at enrolment.
* Uncontrolled hypothyroidism as indicated by a thyroid stimulating hormone (TSH) \> 2 x ULN at enrolment.
* Renal insufficiency: creatinine \> 2.0mg/dl
* Known or suspect alcohol or drug abuse.

Minimum Eligible Age

25 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrick C D'Haese, Prof

Role: STUDY_DIRECTOR

Universiteit Antwerpen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Antwerp

Antwerp, Antwerp, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STAT-AZ-01

Identifier Type: -

Identifier Source: org_study_id